Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | ODC1 | P11926 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073144 | 0.92 | FDPS (0.42) | FDPSPDE3A | |
| SCHEMBL10073146 | 0.86 | LMNA (0.34) | FDPSPDE3A | |
| SCHEMBL8259996 | 0.85 | FDPS (0.32) | FDPSPDE3A | |
| SCHEMBL13334523 | 0.77 | FDPS (0.33) | FDPSPDE3AODC1 | |
| SCHEMBL12848975 | 0.77 | — | — | |
| SCHEMBL10322589 | 0.75 | FDPS (0.50) | FDPSPDE3A | |
| SCHEMBL15492659 | 0.74 | — | — | |
| SCHEMBL14217571 | 0.72 | — | — | |
| Phosphonic Acid SCHEMBL17105021 | 0.72 | FDPS (0.44) | FDPSPDE3AODC1 | |
| SCHEMBL15492660 | 0.71 | EPHX1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170164642-A1 | Preservative System For Acidic Beverages Based On Sequestrants | PEPSICO, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9611284-B2 | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2017-04-04 | — | — | US | disclosed |
| US-9560871-B2 | Preservative system for acidic beverages based on sequestrants | PEPSICO, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9119884-B2 | LLP2A-bisphosphonate conjugates for osteoporosis treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140056855-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-27 | — | — | US | disclosed |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| WO-2012054807-A2 | VACCINES COMPRISING BISPHOSPHONATE AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012046062-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | SHIRE, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2010078069-A1 | PRESERVATIVE SYSTEM FOR ACIDIC BEVERAGES BASED ON SEQUESTRANTS | PEPSICO, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100166917-A1 | Preservative System For Acidic Beverages Based On Sequestrants | PEPSICO, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-7662977-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20080292714-A1 | BONE TARGETING OF DEGRADABLE DRUG FILLED NANOPARTICLES | SEMAFORE PHARMACEUTICALS INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SIGNALRX PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-7396828-B2 | PI-3 kinase inhibitor prodrugs | SEMAFORE PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | FDPS 1999/4885PDE3A 825/4885ODC1 2267/4885 |
| US-20140056855-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | FDPS 1878/4885PDE3A 4282/4885ODC1 4127/4885 |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | PI4KA, PI4KB, PI4K2B | FDPS 1903/4885PDE3A 552/4885ODC1 1835/4885 |
| US-20080292714-A1 | BONE TARGETING OF DEGRADABLE DRUG FILLED NANOPARTICLES | BMP2, BMP6, SOST | FDPS 1012/4885PDE3A 2464/4885ODC1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.